 WESTLAKE VILLAGE, Calif., Sept. 27, 2021 GLOBE NEWSWIRE -- Arcutis Biotherapeutics, Inc. Nasdaq: ARQT, a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology to address the urgent needs of patients living with immune-mediated dermatological diseases and conditions, today announced that four abstracts for Arcutis topical roflumilast program in psoriasis, scalp and body psoriasis, and seborrheic dermatitis will be presented at European Academy of Dermatology and Venereology EADV Congress. Topical roflumilast is a selective and highly potent phosphodiesterase-4 inhibitor being investigated by Arcutis as a non-steroidal topical treatment for multiple inflammatory skin diseases. 